Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age2+
SponsorEisai Inc.
About this trial
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
Eligibility criteria
Qualifiers
Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the treating physician)
Male or female, age at least 2 years at the time of informed consent
Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304
Has a clinical benefit from lorcaserin in the opinion of the treating physician
Disqualifiers
None
Trial design
Treatments tested in this trial
- Lorcaserin
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov